The FDA said it approved cheaper versions of the drug, known chemically as duloxetine, in a variety of strengths for sale by several generic drugmakers, including Teva Pharmaceutical Industries Ltd, Aurobindo Pharma Ltd, Dr. Reddy's Laboratories Ltd, Lupin Ltd, Sun Pharmaceutical Industries and Torrent Pharmaceuticals Ltd..» Read More
NEW YORK, Nov 19- PharMEDium Services LLC, a venture capital-backed provider of pharmacy compounding services to hospitals, is in discussions to sell itself for close to $1 billion, according to people familiar with the matter.
Spending on expensive new specialty drugs for cancer and other ailments will rise to between $230 billion and $240 billion by 2017, up 38 percent from $171 billion last year, the report from the IMS Institute for Healthcare Informatics, a division of healthcare information company IMS Health, said.
AMSTERDAM, Nov 19- Dutch food and chemicals group DSM said on Tuesday it was spinning off its pharmaceuticals division in a $2.6 billion deal with private equity firm JLL, pushing DSM's shares up more than 3 percent. JLL is the majority shareholder in contract drug maker Patheon.
*Diet drugs and plans a hard sell, despite rising obesity. KALUNDBORG, Denmark, Nov 14- Steam rises from pipes at a giant industrial complex on the edge of the Baltic Sea whose success is a testament to the world's diabetes and obesity epidemic.
But use of Merck& Co's widely prescribed Zetia, which is not a statin, and Vytorin, a related drug, will likely not be badly hurt anytime soon, analysts said, because doctors will need time to understand and accept the new guidelines. The Merck drugs have combined annual sales of more than $4 billion, or 10 percent of overall company revenue.
Pfizer Inc, Amgen Inc and a partnership of Regeneron Inc and French drugmaker Sanofi SA are racing to develop the new family of medicines called PCSK9 inhibitors. "I read the new guidelines as a negative for any drugs that aren't statins, including PCSK9 inhibitors," said Jon LeCroy, an analyst with MKM Partners.
Focused on high-risk heart attack and stroke patients, the new recommendation are for aggressive drug therapy to lower cholesterol.
Amazon.com is clashing with Johnson & Johnson amid complaints the online retailer hasn't stopped sales of damaged or expired products.
*Grifols shares up 2.3 percent, Novartis adds 0.5 percent. ZURICH/ MADRID, Nov 11- Switzerland's Novartis has agreed to sell its blood transfusion testing unit to Spain's Grifols for $1.68 billion, in an increasingly buoyant market for healthcare deals.
ZURICH/ MADRID, Nov 11- Switzerland's Novartis has agreed to sell its blood transfusion diagnostics unit to Spain's Grifols for $1.68 billion, in an increasingly buoyant market for pharmaceutical mergers and acquisitions.
FRANKFURT, Nov 8- Germany's Boehringer Ingelheim, the world's largest unlisted drugmaker, is looking to expand its animal health business and is set to make an offer for poultry vaccine and feed additives maker Lohmann, two people familiar with the matter said.
Nov 7- Bristol-Myers Squibb Co said on Thursday that it would no longer conduct research to discover new drugs for hepatitis C, diabetes and neuroscience, but will increase spending on medicines that harness the immune system to fight cancer.
*Offer price of $32/ share is 37 pct above Santarus' Thursday close. Nov 7- Salix Pharmaceuticals Ltd will buy Santarus Inc for about $2.6 billion to boost its portfolio of drugs with a complementary set of products from the specialty pharmaceutical company. The $32 per share offer is a 37 percent premium to Santarus' Thursday close on the Nasdaq.
Gazyva, previously known as GA101, was approved in the United States last week as an initial treatment for patients with chronic lymphocytic leukemia, or CLL, one of the most common forms of blood cancer. It is awaiting approval decisions in Europe and other markets.
TOKYO, Nov 6- The Tokyo Stock Exchange is launching a new index comprised of companies with high return on equity and strong corporate governance to appeal to investors, amid a strong rally in Japanese shares this year.
SYDNEY, Nov 6- With a track record of funding junior miners, Australia's IPO market is now warming up to something that might be just as risky as the diggers- drug makers. Mining stocks have come under pressure over the past year as Australia's decade-long mining investment boom fades and top consumer China takes a slower lane to growth.
Nov 5- U.S.-based specialty pharmaceutical company Endo Health Solutions Inc will buy Canadian peer Paladin Labs Inc to expand its presence in Canada and emerging markets, as generic competition for its top drugs squeeze sales.
*CEO sees pricing pressures in Europe and U.S. in future. COPENHAGEN, Nov 5- Drug pricing is emerging as a key challenge for Novo Nordisk, the world's biggest insulin producer, whose previously unstoppable growth has started to flag, according to the Danish firm's chief executive.
WASHINGTON, Nov 4- In one of the largest health care fraud settlements in U.S. history, Johnson& Johnson will pay $2.2 billion to end civil and criminal investigations into kickbacks to pharmacists and the marketing of pharmaceuticals for off-label uses, U.S.
Johnson & Johnson and its subsidiaries were accused of promoting powerful psychiatric drugs for unapproved uses in children, seniors and disabled patients.